These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 18854347

  • 1. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis.
    Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK.
    Rheumatology (Oxford); 2008 Dec; 47(12):1775-9. PubMed ID: 18854347
    [Abstract] [Full Text] [Related]

  • 2. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH, Lee HJ, Sung IH, Kim TH.
    J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
    [Abstract] [Full Text] [Related]

  • 3. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 19; 86(35):2451-4. PubMed ID: 17156669
    [Abstract] [Full Text] [Related]

  • 4. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.
    Arthritis Rheum; 2009 Nov 15; 61(11):1484-90. PubMed ID: 19877087
    [Abstract] [Full Text] [Related]

  • 5. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.
    Ann Rheum Dis; 2004 Jun 15; 63(6):665-70. PubMed ID: 15037444
    [Abstract] [Full Text] [Related]

  • 6. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC, Chung SJ, Park YB, Lee SK.
    Scand J Rheumatol; 2008 Jun 15; 37(3):173-8. PubMed ID: 18465450
    [Abstract] [Full Text] [Related]

  • 7. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC.
    J Rheumatol; 2005 Oct 15; 32(10):1911-7. PubMed ID: 16206346
    [Abstract] [Full Text] [Related]

  • 8. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug 15; 28(8):1349-51. PubMed ID: 18753057
    [Abstract] [Full Text] [Related]

  • 9. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis.
    Park MC, Lee SW, Choi ST, Park YB, Lee SK.
    Scand J Rheumatol; 2007 Aug 15; 36(2):101-6. PubMed ID: 17476615
    [Abstract] [Full Text] [Related]

  • 10. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
    Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J.
    Ann Rheum Dis; 2008 Sep 15; 67(9):1276-81. PubMed ID: 18006539
    [Abstract] [Full Text] [Related]

  • 11. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
    Chen CH, Liao HT, Chen HA, Liu CH, Liang TH, Wang CT, Tsai CY, Chou CT.
    Rheumatology (Oxford); 2010 Feb 15; 49(2):264-70. PubMed ID: 20008091
    [Abstract] [Full Text] [Related]

  • 12. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K, Deighton C.
    Rheumatology (Oxford); 2007 Mar 15; 46(3):439-41. PubMed ID: 17255137
    [Abstract] [Full Text] [Related]

  • 13. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis.
    Masi L, Ricci L, Zulian F, Del Monte F, Simonini G, Capannini S, De Martino M, Brandi ML, Falcini F.
    J Rheumatol; 2009 Oct 15; 36(10):2308-13. PubMed ID: 19684155
    [Abstract] [Full Text] [Related]

  • 14. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease.
    Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, Lusson JR, Soubrier M.
    Rheumatology (Oxford); 2008 Aug 15; 47(8):1203-7. PubMed ID: 18524805
    [Abstract] [Full Text] [Related]

  • 15. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.
    Rheumatology (Oxford); 2008 Jun 15; 47(6):780-8. PubMed ID: 18388148
    [Abstract] [Full Text] [Related]

  • 16. Expression of osteopontin in chronic rhinosinusitis with and without nasal polyps.
    Lu X, Zhang XH, Wang H, Long XB, You XJ, Gao QX, Cui YH, Liu Z.
    Allergy; 2009 Jan 15; 64(1):104-11. PubMed ID: 19076536
    [Abstract] [Full Text] [Related]

  • 17. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
    Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J.
    Ann Rheum Dis; 2008 Apr 15; 67(4):511-7. PubMed ID: 17644552
    [Abstract] [Full Text] [Related]

  • 18. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.
    Xu M, Lin Z, Deng X, Li L, Wei Y, Liao Z, Li Q, Wei Q, Hu Z, Zhang Y, Lin Q, Huang J, Li T, Pan Y, Wu Y, Jin O, Yu B, Gu J.
    Rheumatology (Oxford); 2011 Aug 15; 50(8):1466-72. PubMed ID: 21441550
    [Abstract] [Full Text] [Related]

  • 19. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
    Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Lambert R, Hansen A, Østergaard M.
    Ann Rheum Dis; 2011 Aug 15; 70(8):1375-81. PubMed ID: 21551511
    [Abstract] [Full Text] [Related]

  • 20. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis.
    Lange U, Teichmann J, Stracke H.
    Eur J Med Res; 2000 Dec 29; 5(12):507-11. PubMed ID: 11147993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.